A panelist discusses how managing biosimilars requires close collaboration between payers and health systems to optimize patient care and cost savings, while sharing insights about program implementation challenges across different care settings and emphasizing the importance of robust operational frameworks.
A panelist discusses how their institution is proactively adapting their formulary review processes and infrastructure to handle the growing biosimilar pipeline, while anticipating increased competition will drive strategic shifts in contracting and necessitate more flexible approaches to formulary management in the coming years.
A panelist discusses how their institution implements robust safety protocols including distinct labeling, electronic health record alerts, and staff education to prevent dispensing errors when managing multiple biosimilars, while also conducting targeted educational outreach to address stakeholder concerns about interchangeability.
A panelist discusses how payer contract requirements and reimbursement policies significantly influence their institution’s biosimilar adoption strategy, requiring careful analysis of net cost benefits when weighing potential savings against the operational complexities of managing multiple products.
A panelist discusses how their institution prioritizes cost savings and reliable supply chain considerations when selecting biosimilars for formulary inclusion, while also weighing switching study evidence, addressing stakeholder concerns through education, and implementing protocols to overcome barriers such as electronic health record integration and prior authorization challenges.
A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while prioritizing operational efficiency, patient access, and seamless transitions between reference products and biosimilars.
